

Naoto Fujiwara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4363379/publications.pdf>

Version: 2024-02-01

63
papers

3,550
citations

279798

23
h-index

144013

57
g-index

64
all docs

64
docs citations

64
times ranked

5835
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma-Signature-Model for End-Stage Liver Disease Score to Predict Survival in Severe Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 651-657.	4.4	3
2	A Blood-Based Prognostic Liver Secretome Signature Predicts Long-term Risk of Hepatic Decompensation in Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1188-e1191.	4.4	6
3	Liver cancer risk-predictive molecular biomarkers specific to clinico-epidemiological contexts. <i>Advances in Cancer Research</i> , 2022, , .	5.0	0
4	DETECT: Development of Technologies for Early HCC Detection. <i>Gastroenterology</i> , 2022, 163, 21-27.	1.3	4
5	Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	33
6	Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. <i>Gastroenterology</i> , 2022, 162, 1210-1225.	1.3	17
7	Improved prognosis of hepatitis C-related hepatocellular carcinoma in the era of direct-acting antivirals. <i>Hepatology Communications</i> , 2022, 6, 2496-2512.	4.3	4
8	Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	40
9	Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation. <i>JCI Insight</i> , 2022, 7, .	5.0	4
10	Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. <i>Gut</i> , 2021, 70, 157-169.	12.1	57
11	Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. <i>Journal of Gastroenterology</i> , 2021, 56, 261-273.	5.1	28
12	Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals. <i>Liver Cancer</i> , 2021, 10, 309-319.	7.7	16
13	A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. <i>Med</i> , 2021, 2, 836-850.e10.	4.4	31
14	A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. <i>Nature Communications</i> , 2021, 12, 5525.	12.8	21
15	Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients. <i>Journal of Gastroenterology</i> , 2020, 55, 227-243.	5.1	29
16	Gene signature and MELD score and alcohol relapse determine long-term prognosis of patients with severe alcoholic hepatitis. <i>Liver International</i> , 2020, 40, 565-570.	3.9	12
17	Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. <i>Journal of Clinical Medicine</i> , 2020, 9, 3843.	2.4	10
18	Viral Exposure Signature Associated with Liver Cancer Risk. <i>Trends in Molecular Medicine</i> , 2020, 26, 711-713.	6.7	2

#	ARTICLE	IF	CITATIONS
19	A genome-wide gain-of-function screen identifies CDKN2C as a HBV host factor. <i>Nature Communications</i> , 2020, 11, 2707.	12.8	11
20	Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 2522-2534.	3.9	20
21	Omics-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases. <i>Hepatology Research</i> , 2020, 50, 817-830.	3.4	13
22	Steatohepatic Variant of Hepatocellular Carcinoma Is Associated With Both Alcoholic Steatohepatitis and Nonalcoholic Steatohepatitis. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1406-1412.	3.7	15
23	Risk Factors of Hepatocellular Carcinoma for Precision Personalized Care. <i>Molecular and Translational Medicine</i> , 2019, , 3-25.	0.4	6
24	Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. <i>Scientific Reports</i> , 2019, 9, 10663.	3.3	57
25	Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of Hepatitis C Virus-Infected Cells and Liver to Identify Pathways Associated With Disease Development. <i>Gastroenterology</i> , 2019, 157, 537-551.e9.	1.3	71
26	MPIC: Molecular Prognostic Indicators in Cirrhosis Database for Clinical Context-Specific in Silico Prognostic Biomarker Validation. <i>Frontiers in Genetics</i> , 2019, 10, 830.	2.3	1
27	Shared and Tissue-Specific Expression Signatures between Bone Marrow from Primary Myelofibrosis and Essential Thrombocythemia. <i>Experimental Hematology</i> , 2019, 79, 16-25.e3.	0.4	8
28	Dose and Duration of Aspirin Use to Reduce Incident Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 70, 2216-2217.	7.3	7
29	HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response. <i>Gastroenterology</i> , 2019, 156, 2313-2329.e7.	1.3	184
30	Hepatocellular Carcinoma Risk Stratification by Genetic Profiling in Patients with Cirrhosis. <i>Seminars in Liver Disease</i> , 2019, 39, 153-162.	3.6	5
31	Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma. <i>Cell Metabolism</i> , 2019, 29, 174-182.e5.	16.2	246
32	Ischemic complications after percutaneous radiofrequency ablation of liver tumors: Liver volume loss and recovery. <i>Hepatology Research</i> , 2019, 49, 453-461.	3.4	4
33	Liver stiffness measurements in chronic hepatitis C: Treatment evaluation and risk assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 921-928.	2.8	18
34	Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy. <i>Journal of Hepatology</i> , 2019, 70, 78-86.	3.7	71
35	A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update. <i>Journal of Gastroenterology</i> , 2019, 54, 367-376.	5.1	156
36	Precision Locoregional Therapies for Hepatocellular Carcinoma: Percutaneous Ablation and Radiotherapy. <i>Molecular and Translational Medicine</i> , 2019, , 195-224.	0.4	3

#	ARTICLE	IF	CITATIONS
37	CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. <i>Gut</i> , 2018, 67, 1493-1504.	12.1	131
38	Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis. <i>Gastroenterology</i> , 2018, 154, 965-975.	1.3	41
39	A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. <i>Journal of Hepatology</i> , 2018, 69, 385-395.	3.7	330
40	Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. <i>Journal of Hepatology</i> , 2018, 68, 526-549.	3.7	506
41	Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 317-325.	3.3	12
42	Lipid Metabolic Reprogramming in Hepatocellular Carcinoma. <i>Cancers</i> , 2018, 10, 447.	3.7	107
43	Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. <i>Nature Communications</i> , 2018, 9, 4962.	12.8	111
44	Serum levels of ferritin do not affect the prognosis of patients with hepatocellular carcinoma undergoing radiofrequency ablation. <i>PLoS ONE</i> , 2018, 13, e0200943.	2.5	4
45	Hepatic IRS1 and β -catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients. <i>Journal of Gastroenterology</i> , 2018, 53, 1261-1275.	5.1	25
46	Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. <i>Cell</i> , 2018, 174, 1200-1215.e20.	28.9	96
47	Family history is an independent risk factor for the progression of gastric atrophy among patients with <i>Helicobacter pylori</i> infection. <i>United European Gastroenterology Journal</i> , 2017, 5, 32-36.	3.8	25
48	The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 65, 1272-1273.	3.7	79
49	Impact of serum ferritin level on hepatocarcinogenesis in chronic hepatitis C patients. <i>Hepatology Research</i> , 2016, 46, 259-268.	3.4	13
50	Slight elevation of high-sensitivity C-reactive protein to predict recurrence and survival in patients with early stage hepatitis C-related hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, 645-655.	3.4	10
51	Serum Alpha-Fetoprotein Has High Specificity for the Early Detection of Hepatocellular Carcinoma After Hepatitis C Virus Eradication in Patients. <i>Medicine (United States)</i> , 2015, 94, e901.	1.0	16
52	Comparison of improved prognosis between hepatitis B- and hepatitis C-related hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, E99-E107.	3.4	15
53	Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2015, 63, 131-140.	3.7	538
54	Impact of serum levels of interleukin-6 and adiponectin on all-cause, liver-related, and liver-unrelated mortality in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 379-388.	2.8	19

#	ARTICLE	IF	CITATIONS
55	Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. <i>Journal of Gastroenterology</i> , 2015, 50, 350-360.	5.1	144
56	Spontaneous clearance of serum hepatitis C virus RNA during the clinical course of hepatocellular carcinoma in patients with chronic hepatitis C. <i>Hepatology Research</i> , 2014, 44, E32-7.	3.4	8
57	Cause-specific mortality associated with aging in patients with hepatocellular carcinoma undergoing percutaneous radiofrequency ablation. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1039-1046.	1.6	10
58	Drastically Reduced Neoplastic Seeding Related to Radiofrequency Ablation for Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2014, 109, 774-776.	0.4	10
59	Impact of IL28B Genetic Variation on HCV-Induced Liver Fibrosis, Inflammation, and Steatosis: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e91822.	2.5	30
60	Frequency of and Predictive Factors for Vascular Invasion after Radiofrequency Ablation for Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e111662.	2.5	24
61	Changes in Risk of Immediate Adverse Reactions to Iodinated Contrast Media by Repeated Administrations in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e76018.	2.5	15
62	IGF-II Producing Hepatocellular Carcinoma Treated with Sorafenib: Metabolic Complications and a Foresight to Molecular Targeting Therapy to the IGF Signal. <i>Case Reports in Gastroenterology</i> , 2012, 6, 784-789.	0.6	9
63	A Blood-Based Prognostic Liver Secretome Signature and Long-Term Hepatocellular Carcinoma Risk in Advanced Liver Fibrosis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0